Q-omics provides the consensus-scored SCRT2 profile across patient tissues and cancer cell-line models. SCRT2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SCRT2 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, SCRT2 RNA expression shows 8,360 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight LIHC, STAD, and PCPG as cancer lineages where SCRT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCRT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCRT2 survival associations across molecular data types. SCRT2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCRT2 RNA expression–survival associations across cancer types. High SCRT2 expression shows unfavorable associations in LIHC, SKCM, UCEC, HNSC and LUAD, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for SCRT2 RNA expression.
This table summarizes SCRT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCRT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCRT2 shows higher tumor expression in STAD, KIRC and LUSC. The STAD box plot shows higher SCRT2 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .021).
This table shows molecular features associated with SCRT2 in patient tissues and cancer cell lines. In patient samples, SCRT2 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, SCRT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and OVARY.
